Alexion Pharmaceuticals Inc. (ALXN) Acquires Taligen Therapeutics for $111 Million and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
1/31/2011 7:01:12 AM
More...
|
Taligen Therapeutics CEO Abbie Celniker Honored with Mass High Tech 2010 All-Star Award
10/29/2010 9:58:44 AM
More...
|
Taligen Therapeutics Granted Patent for Lead Product Candidate, TT30, and Other Compounds Targeting the Complement System
8/23/2010 8:12:36 AM
More...
|
Taligen Therapeutics Closes $10 Million Series B Financing Tranche
8/23/2010 7:00:13 AM
More...
|
Taligen Therapeutics Pipeline Candidates Highlighted at XXIII International Complement Workshop
8/2/2010 8:51:51 AM
More...
|
Taligen Therapeutics CEO Abbie Celniker Appointed to Massachusetts Life Sciences Center Board of Directors
7/29/2010 12:05:29 PM
More...
|
Taligen Therapeutics Receives Bioscience Company of the Year Award; CSO Holers Honored with Lifetime Achievement Award
6/23/2010 6:35:28 AM
More...
|
Taligen Therapeutics Appoints Industry Leader, John Maraganore, as Director
4/15/2010 10:09:35 AM
More...
|
Taligen Therapeutics Announces Key Additions to Management Team
4/15/2010 10:08:47 AM
More...
|
Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
12/1/2008 8:59:28 AM
More...
|
|